LXRX
Lexicon Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$1.23
+0.05 (+4.24%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 38.40M | 68.34M | 62.90M | 66.37M |
| Net Income | -247,640,972 | 19.40M | 18.23M | 21.89M |
| EPS | — | — | — | — |
| Profit Margin | -644.8% | 28.4% | 29.0% | 33.0% |
| Rev Growth | +369.7% | +10.7% | +9.3% | +0.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 99.06M | 183.67M | 161.72M | 163.58M |
| Total Equity | 144.15M | 200.03M | 220.65M | 240.93M |
| D/E Ratio | 0.69 | 0.92 | 0.73 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -227,749,019 | 29.54M | 28.34M | 30.60M |
| Free Cash Flow | — | 10.65M | 12.86M | 11.69M |